440.2: Immune response and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (adjuvanted RSVPreF3) in immunocompromised (IC) adults with lung or kidney transplant compared to non-IC adults up to 12 months post-vaccination.
Year: 2026
Type: article
Source: Transplantation
Authors: Catherine Small, Deepali Kumar, Anum Abbas, Ana Sanchez-Fructuoso, Shigeyoshi Yamanaga, Virginia Perez-Gonzales, Hristos Karakizlis, Michael Nissen, Pyoeng Gyun Choe, Vera Paloschi, Steve J. Chadban, Hiwot Amare Hailemariam, Catherine Gerard, Marie-Pierre David, Dominique Descamps, Clara Agutu, Kemi Oluwayi, Veronica Hulstrøm
Institutions: Weill Cornell Medicine, University Health Network, University of Nebraska Medical Center, Universidad Complutense de Madrid, Hospital Clínico San Carlos, Japanese Red Cross Kumamoto Hospital, Hospital Universitario 12 De Octubre, Justus-Liebig-Universität Gießen, Royal Brisbane and Women's Hospital, Prince Charles Hospital, Seoul National University Hospital, IRCCS Ospedale San Raffaele, The University of Sydney, Royal Prince Alfred Hospital, GlaxoSmithKline (Belgium), GlaxoSmithKline Research & Development Limited (United Kingdom)
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204784352